New pill takes aim at 'Undruggable' KRAS cancers
NCT ID NCT06973564
First seen Nov 12, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This study tests an experimental oral drug called JAB-23E73 in adults with advanced solid tumors that have a KRAS alteration. The goal is to find a safe dose and see if it can shrink tumors. About 294 participants will take the pill, and researchers will monitor side effects and anti-cancer activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Foundation
RECRUITINGCleveland, Ohio, 44195, United States
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAB-23E73 (a pan-KRAS inhibitor pill)
What this could lead to
If successful, this could lead to a new oral treatment option for several hard-to-treat cancers driven by KRAS mutations.
What could go wrong
This is an early phase 1/2a trial, so safety and dosing are still being figured out. Many experimental cancer drugs fail to show enough benefit in later stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.